vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $45.9M, roughly 1.4× California BanCorp \ CA). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 35.8%, a 3.6% gap on every dollar of revenue. California BanCorp \ CA produced more free cash flow last quarter ($56.9M vs $43.5M).

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

BCAL vs SLNO — Head-to-Head

Bigger by revenue
SLNO
SLNO
1.4× larger
SLNO
$66.0M
$45.9M
BCAL
Higher net margin
SLNO
SLNO
3.6% more per $
SLNO
39.4%
35.8%
BCAL
More free cash flow
BCAL
BCAL
$13.5M more FCF
BCAL
$56.9M
$43.5M
SLNO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BCAL
BCAL
SLNO
SLNO
Revenue
$45.9M
$66.0M
Net Profit
$16.4M
$26.0M
Gross Margin
98.3%
Operating Margin
48.8%
33.5%
Net Margin
35.8%
39.4%
Revenue YoY
0.8%
Net Profit YoY
-2.1%
134.0%
EPS (diluted)
$0.50
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
SLNO
SLNO
Q4 25
$45.9M
Q3 25
$45.2M
$66.0M
Q2 25
$44.3M
$32.7M
Q1 25
$44.8M
Q4 24
$45.5M
Q3 24
$38.1M
Q2 24
$22.2M
Q1 24
$21.9M
Net Profit
BCAL
BCAL
SLNO
SLNO
Q4 25
$16.4M
Q3 25
$15.7M
$26.0M
Q2 25
$14.1M
$-4.7M
Q1 25
$16.9M
Q4 24
$16.8M
Q3 24
$-16.5M
Q2 24
$190.0K
Q1 24
$4.9M
Gross Margin
BCAL
BCAL
SLNO
SLNO
Q4 25
Q3 25
98.3%
Q2 25
97.9%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
BCAL
BCAL
SLNO
SLNO
Q4 25
48.8%
Q3 25
48.3%
33.5%
Q2 25
45.3%
-20.0%
Q1 25
52.8%
Q4 24
52.2%
Q3 24
-59.1%
Q2 24
1.3%
Q1 24
33.1%
Net Margin
BCAL
BCAL
SLNO
SLNO
Q4 25
35.8%
Q3 25
34.7%
39.4%
Q2 25
31.8%
-14.4%
Q1 25
37.6%
Q4 24
37.7%
Q3 24
-43.2%
Q2 24
0.9%
Q1 24
22.5%
EPS (diluted)
BCAL
BCAL
SLNO
SLNO
Q4 25
$0.50
Q3 25
$0.48
$0.47
Q2 25
$0.43
$-0.09
Q1 25
$0.52
Q4 24
$0.54
Q3 24
$-0.59
Q2 24
$0.01
Q1 24
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$399.9M
$498.9M
Total DebtLower is stronger
$33.8M
Stockholders' EquityBook value
$576.6M
$494.8M
Total Assets
$4.0B
$599.9M
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
SLNO
SLNO
Q4 25
$399.9M
Q3 25
$559.2M
$498.9M
Q2 25
$430.1M
$286.8M
Q1 25
$439.2M
Q4 24
$388.2M
Q3 24
$614.4M
Q2 24
$104.7M
Q1 24
$86.5M
Total Debt
BCAL
BCAL
SLNO
SLNO
Q4 25
$33.8M
Q3 25
$33.4M
Q2 25
$52.9M
Q1 25
$70.3M
Q4 24
$69.7M
Q3 24
$69.1M
Q2 24
$42.9M
Q1 24
$44.9M
Stockholders' Equity
BCAL
BCAL
SLNO
SLNO
Q4 25
$576.6M
Q3 25
$564.7M
$494.8M
Q2 25
$547.6M
$240.1M
Q1 25
$531.4M
Q4 24
$511.8M
Q3 24
$498.1M
Q2 24
$293.2M
Q1 24
$292.5M
Total Assets
BCAL
BCAL
SLNO
SLNO
Q4 25
$4.0B
Q3 25
$4.1B
$599.9M
Q2 25
$4.0B
$332.3M
Q1 25
$4.0B
Q4 24
$4.0B
Q3 24
$4.4B
Q2 24
$2.3B
Q1 24
$2.3B
Debt / Equity
BCAL
BCAL
SLNO
SLNO
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
SLNO
SLNO
Operating Cash FlowLast quarter
$57.3M
$43.5M
Free Cash FlowOCF − Capex
$56.9M
$43.5M
FCF MarginFCF / Revenue
124.1%
65.8%
Capex IntensityCapex / Revenue
0.8%
0.0%
Cash ConversionOCF / Net Profit
3.49×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
SLNO
SLNO
Q4 25
$57.3M
Q3 25
$16.0M
$43.5M
Q2 25
$13.4M
$-12.6M
Q1 25
$7.0M
Q4 24
$50.3M
Q3 24
$18.3M
Q2 24
$309.0K
Q1 24
$8.1M
Free Cash Flow
BCAL
BCAL
SLNO
SLNO
Q4 25
$56.9M
Q3 25
$15.9M
$43.5M
Q2 25
$13.4M
$-12.6M
Q1 25
$6.9M
Q4 24
$49.7M
Q3 24
$18.1M
Q2 24
$171.0K
Q1 24
$8.0M
FCF Margin
BCAL
BCAL
SLNO
SLNO
Q4 25
124.1%
Q3 25
35.1%
65.8%
Q2 25
30.2%
-38.6%
Q1 25
15.3%
Q4 24
109.2%
Q3 24
47.5%
Q2 24
0.8%
Q1 24
36.4%
Capex Intensity
BCAL
BCAL
SLNO
SLNO
Q4 25
0.8%
Q3 25
0.2%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.2%
Q4 24
1.2%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.4%
Cash Conversion
BCAL
BCAL
SLNO
SLNO
Q4 25
3.49×
Q3 25
1.02×
1.67×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons